DUBAI, UAE / ACCESSWIRE / June 22, 2020 / Be it life insurance, health insurance, or car insurance, investing in an insurance policy can mean the difference between a bad situation and a devastating one. Though none of us likes to linger on the thought, the repercussions of a loved one dying can cost upwards of US$11,000 for the funeral alone, not to mention the mortgage or private debt that person may be carrying. But many of us put purchasing insurance off, believing it to be a far greater financial drain than it is. In fact, according to LIMRA, 80% of people overestimate the cost of term life insurance. Millennials, in particular, overestimate the cost by a whopping 213%. But insurance schemes usually work out to be extremely insignificant in terms of ongoing costs, begging the question of why there remain so many uninsured nonelderly people around the world today.

Thankfully there are now online insurance service providers like Alfred's InsuranceMarket.ae™ that take the guesswork and research out of finding affordable and reliable insurance cover. With a vast range of insurance offerings, from car insurance Dubai to motor fleet insurance, yacht insurance, medical malpractice insurance, event insurance, public liability, bike insurance, business insurance, contract insurance, life insurance and more, InsuranceMarket.ae™ has been successfully serving the needs of its insurance clients for more than two decades in the UAE.

Part of AFIA Insurance Brokerage Services L.L.C, InsuranceMarket.ae™ is among the leading insurance service provider for most of the insurance companies in the UAE, including names like AXA, RSA, Orient, Tokio Marine, and Noor Takaful. With dedicated and qualified personal advisors – as opposed to customer service agents operating in overseas call centers – to help guide customers through the process, explain the benefits and select the best plan for them, it is no wonder InsuranceMarket.ae™ has quickly garnered a reputation as the UAE's highest-rated insurance provider.

InsuranceMarket.ae™ was founded in 2010 by AFIA's CEO Avinash Babur ACII, as a digital-first insurance service platform designed to make the insurance process more accessible to consumers in the Middle East. As the son of AFIA's founder Nandu Babur ACII, an insurance industry veteran who has been practicing insurance broking in the UAE since 1980, InsuranceMarket.ae™ remains a family-run business in every way, with transparency and reliability as its core business values.

"We pride ourselves on consistently achieving AFIA's four pillars: Attractive price, friendly service, ideal security, and adequate cover," explained Mr.Babur ACII. "And we wish to continue our commitment to helping our customers become secure whilst ensuring they save time and money when doing so."

To date, InsuranceMarket.ae™ and AFIA have successfully served the needs of more than 200,000 clients, thanks to a team of over 200 insurance professionals committed to helping customers with all their retail and business insurance requirements.

"Our growth and success since 1995 would not be possible without our Management Team which has been able to successfully execute our customer obsession strategy," said Mr. Babur ACII. "We are obsessed with conveniently and cost-effectively making our clients' lives secure, and we believe it shows."

Location: Dubai, UAE
Contact: Hitesh Motwani, +971 4 818 5201

SOURCE: InsuranceMarket.ae

ReleaseID: 594869

NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Baidu, Inc. ("Baidu" or "the Company") (NASDAQ:BIDU) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Baidu securities between March 16, 2019 through April 7, 2020 , both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/bidu.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Baidu's feed services were not in compliance with applicable Chinese regulatory standards; (2) the foregoing noncompliance subjected the Company to a heightened risk of regulatory enforcement, including the removal or suspension of certain of Baidu's services and products; (3) accordingly, the Company's revenues derived from online marketing services were unlikely to be sustainable; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/bidu or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Baidu you have until June 22, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 594656

Convalescent Plasma Therapy, which involves extracting plasma from a formerly infected patient and introducing it into currently symptomatic patients, has provided a ray of optimism amongst medical practitioners about eradicating the virus. Convalescent plasma is known to contain the relevant antibodies needed to inhibit the growth of the coronavirus.

DUBLIN, IRELAND / ACCESSWIRE / June 22, 2020 / Blood transfusion has emerged as an important component of contemporary healthcare. Rising incidences of chronic conditions such as leukemia, thalassemia and aplastic anemia have augmented blood transfusion rates, compelling pharmaceutical and healthcare companies to accelerate research and development in enhancing the procedure by the introduction of technologically-advanced testing kits, assays and instruments for different healthcare settings.

While significant progress has been made in this field, the risks associated with blood transfusions have equally heightened. Fortunately, these transfusion transmitted infections are entirely preventable with the use of nucleic acid neutralizing additives or immunoglobulins to destroy pathogens.

The COVID-19 pandemic has opened up new avenues for research in enhancing blood transfusion technologies in order to find a potential cure for the disease. With the signs of a possible vaccine or drugs to eliminate SARS-CoV-2 being very far away on the horizon, blood transfusions could play a critical role in boosting immunity against the coronavirus.

A series of experiments involving plasma transfusions yielded positive results with regard to the recovery of COVID-19 patients. The Proceedings of the National Academy of Sciences (PNAS), an American journal, reported that all ten patients who were administered the convalescent plasma from formerly infected patients recovered within 3 days of its transfusion. Based on these trends, the blood transfusion diagnostics market is poised to embark on a healthy growth trajectory in the future.

"An amalgamation of chronic conditions and blood loss due to external stimuli such as road accidents, injuries and surgical procedures have provided a wide platform for blood transfusion diagnostics to flourish. Research is underway to develop artificial blood solely for the purpose of transporting oxygen and carbon-dioxide which would prove useful for patients who suffer from blood disorders, providing a possible breakthrough in blood transfusion diagnostics," says a Fact.MR analyst.

Request a report sample of a 150+ pages to gain comprehensive market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4720

Global Blood Transfusion Diagnostics Market- Key Takeaways

The global blood transfusion diagnostics market will expand positively at a CAGR of over 6% between 2020 and 2025;
Blood transfusion kits & reagents register extensive usage, attributed to a burgeoning number of blood transfusions for several chronic ailments;
North America remains at the forefront of blood transfusion diagnostics due to increasing proportion of blood banks and use of sophisticated technology. Asia-Pacific is set to expand rapidly attributed to rising medical tourism in the wake of reduced costs;
A majority of blood transfusions occur at blood banks, hence its dominant share in the global blood transfusion diagnostics market. Blood banks are well-equipped to conduct multiple transfusions due to possession of adequate equipment;
The ever-prevalent risk of contracting transfusion transmitted infections (TTIs) will augment the popularity of molecular disease screening in terms of applications of blood transfusion diagnostics.

Global Blood Transfusion Diagnostics Market- Driving Factors

Implementation of protocols for donor blood disease screening and mandatory use of nucleic acid tests for hepatitis C & B and HIV screening will provide traction to the market.
Collaborations between non-profit organizations and government agencies will increasing funding for blood transfusion diagnostic tests.
Increased volume of surgical procedures, increasing number of road accidents and chronic blood conditions leverage the scope of the market.

Global Blood Transfusion Diagnostics Market- Leading Impediments

Fragmented transfusion services lead to inconsistencies in blood transfusion management, attributed to a decentralized monitoring system, which is leading to shortages of blood availability in certain countries like India.
Rapid increase in automation is not consistent with the availability of skilled technicians adept at utilizing transfusion equipment.
There is a general decline in the overall blood donation rates largely due to the fears of contracting TTIs.

Anticipated Market Impact of COVID-19

Since its onset, the novel coronavirus pandemic has brought the whole world to its knees. Healthcare settings have been experiencing immense pressure while coping with the exponentially rising cases on a daily basis. Hospitals are facing immense shortages of essential equipment, beds and testing facilities. Leading pharmaceutical and healthcare companies are leaving no stone unturned to maintain a continuity of operations in healthcare settings by supplying essential equipment at more flexible terms. Simultaneously, copious research is being conducted to develop possible cures for this deadly virus.

In the case of blood transfusion diagnostics, a silver lining is visible to all stakeholders. Research and use cases prove that patients who have recovered from COVID-19 develop certain antibodies against the novel coronavirus in their bloodstream. Thus, if one were to extract these antibodies and inject them into an infected patient, they would recover faster and fatalities could be prevented until an appropriate antiviral drug or vaccine is out in the market. Banking on this trend, healthcare specialists are optimistic about the eradication of the pandemic. As a consequence, the number of blood transfusions for extracting these antibodies is anticipated to rise in the near-term.

Discover more about the global blood transfusion diagnostics market consisting of 79 figures and 30 data tables, along with the table of contents. You can find the market segmentation on

https://www.factmr.com/report/4720/blood-transfusion-diagnostics-market

Competition Landscape

The global blood transfusion diagnostics market is characterized by high competitive rivalry with a fragmented market and the availability of a wide range of blood transfusion products. Some prominent players include Grifols S.A., CSL Behring, Immucor, Inc., Abbott Laboratories, QUOTIENT Limited, F. Hoffmann-La Roche, Bio-Rad Laboratories, DiaSorin S.p.A and Ortho Clinical Laboratories to name a few. Unceasing innovations in blood transfusion technologies, collaborations with other players and product launches characterize the strategies adopted by the market players to consolidate their footprints in the industry. Besides these strategies, companies are investing heavily in plasma fractionation, attributed to the urgent need for addressing the coronavirus pandemic. Plasma fractionation is also beneficial for a host of other ailments too such as immunodeficiencies, coagulation and pulmonary disorders and trauma.

More on the Report

Fact.MR offers detailed insights on the global blood transfusion diagnostics market by providing valuable historical and future projections. The market has segmented on the basis of product type (instruments and kits & reagents), application (blood grouping and disease screening (molecular disease screening and serological disease screening)) and end-user (hospitals, diagnostic laboratories, blood banks, plasma fractionation companies and others) across five regions (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa).

Explore Extensive Coverage of Fact.MR's Healthcare Domain

Monopolar Electrosurgery Market: Fact.MR's exhaustive coverage on the monopolar electrosurgery market provides comprehensive insights on key market indicators, segment-wise revenue shares, regional profiles and competition structure across the forecast period 2020-2025.

Medical Education Market: Explore how medical education has been radically transformed with the integration of information technology and technological breakthroughs in the pharmaceutical industry, along with future growth projections for the forecast period 2020-2027 in Fact.MR's recently published report.

Medical Device Contract Manufacturing Market: Acquire in-depth insights on key market players' strategies to acquire manufacturing contracts for medical devices across emerging markets for the period 2020-2026.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the ICT sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1469/global-blood-transfusion-diagnostics-market

SOURCE: Fact.MR

ReleaseID: 594725

NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Baidu, Inc. (NASDAQ:BIDU)

CONTACT JAKUBOWITZ ABOUT BIDU:
https://claimyourloss.com/securities/baidu-inc-loss-submission-form/?id=7453&from=1

Class Period: March 16, 2019 – April 7, 2020

Lead Plaintiff Deadline: June 22, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Baidu's feed services were not in compliance with applicable Chinese regulatory standards; (ii) the foregoing noncompliance subjected the Company to a heightened risk of regulatory enforcement, including the removal or suspension of certain of Baidu's services and products; (iii) accordingly, the Company's revenues derived from online marketing services were unlikely to be sustainable; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

SCWorx Corp. (NASDAQ:WORX)

CONTACT JAKUBOWITZ ABOUT WORX:
https://claimyourloss.com/securities/scworx-corp-loss-submission-form/?id=7453&from=1

Class Period: April 13, 2020 – April 17, 2020

Lead Plaintiff Deadline: June 29, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) SCWorx's supplier for COVID-19 tests had previously misrepresented its operations; (2) SCWorx's buyer was a small company that was unlikely to adequately support the purported volume of orders for COVID-19 tests; (3) as a result, the Company's purchase order for COVID-19 tests had been overstated or entirely fabricated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Groupon, Inc. (NASDAQ:GRPN)

CONTACT JAKUBOWITZ ABOUT GRPN:
https://claimyourloss.com/securities/groupon-inc-loss-submission-form/?id=7453&from=1

Class Period: November 4, 2019 – February 18, 2020

Lead Plaintiff Deadline: June 29, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing fewer customer engagements in its Goods category; (2) Groupon relied on its Goods category to drive its sales, especially during the holiday season; (3) as a result of the foregoing, the Company was likely to experience reduced sales; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

ReleaseID: 594730

CALGARY, AB and SAN ANTONIO, TX / ACCESSWIRE / June 22, 2020 / Nexera Energy Inc. (TSXV:NGY)(OTC PINK:EMBYF) (the "Company" or "Nexera") is pleased to announce that the Company has commenced operations to survey and permit a new well drilling location on the Huebinger lease at the Company's Wooden Horse project in South Texas.

The proposed Huebinger E1 well represents the next phase of drilling at Wooden Horse. Using seismic interpretation and well control, the Company will drill the Huebinger well structurally up-dip from the producing Kuhn 3 and Kuhn A5 wells. The Huebinger well will be drilled to the top of the Austin Chalk formation where oil production is coming from a water drive system with low decline rates. The Company is currently producing approximately 25 bopd from this formation in the Kuhn wells, and the Company anticipates significantly better results from the up-dip location chosen for the Huebinger well.

With WTI oil prices currently in the USD $40.00 range, drilling costs significantly discounted compared to earlier in the year, and facilities including electricity already in place, the Company is confident in the economics of drilling the Huebinger well at this time. It is anticipated that surveying and permitting will be completed within the next two weeks, with drilling operations to begin before August 1, 2020.

About Nexera Energy Inc.

Nexera Energy Inc. (TSX Venture: NGY) is an energy company with oil producing properties in Southwest Texas. Nexera is owner and operator of the Lavernia, Wooden Horse and Nash Creek Projects. Additionally, the Company owns and operates various working interests in the HugoCellR, Cotulla, and MarPat partnerships. The Company also owns 75% of Production Resources Inc., a South Texas oil company.

For further information, please contact:

Nexera Energy Inc. President, Shelby D. Beattie, by telephone at (403) 262-6000
Email: info@ebyinc.com
www.nexeraenergy.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Nexera Energy Inc

ReleaseID: 594719

LAS VEGAS, NV / ACCESSWIRE / June 22, 2020 / Players Network Inc. (OTCPINK:PNTV) announced today that it has filed for Chapter 11 reorganization.

This filing will provide the company the opportunity to reorganize its debt while also dealing with what it believes to be predatory lenders affecting the company's stock. As disclosed in the filing, the company reserves its right to file adversary claims against these lenders.

A proposed debt restructuring plan was filed with the courts and the debt holders which may result in a significant debt reduction paid over 5 years and simultaneously reduce ,and possibly eliminate, the convertible overhang on the company's stock. While nothing can be assured, the company is confident that it will be able to arrive at a reasonable creditor settlement as soon as the company can get in front of the courts in about 60 days depending on scheduling.

This filing is the first step in a strategic plan to reorganize the company, develop stability, and bring value to its shareholders. Additional details regarding the company's plan will be released shortly in line with the Chapter 11 guidelines.

Mark Bradley CEO of Players Network said, The debt combined with "The COVID 19 pandemic, which shuttered Las Vegas, essentially destroyed our sources of revenue and left the board with no option but to seek chapter 11 protection. I want to say for myself, the board, and our advisors that we are bullish about our reorganization plans and believe this filing is in the best interest of our shareholders. As we progress over the next weeks, these plans will be fully disclosed and outlined to our shareholders."

About Player's Network (PNTV.PK)

Players Network is a publicly traded corporation celebrating its 30th year as a media company whose primary business is focused in television and video production, delivery platforms, network development, and new media technology, platforms, and content. The Company subsequently created, developed, and launched a broadband network, "Weed TV". The company has invested into Green Leaf Farms for the management of a HEMP and Cannabis business in North Las Vegas and Green Leaf Farms International, Inc for the development of those businesses outside the United States.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: inability to gain or maintain licenses, reliance on unaudited statements, the Company's need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company's products, and other risks. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Contact:
David Klepinger
Email: dklepinger@playersnetwork.com
Office: 702-886-8018

SOURCE: Players Network, Inc.

ReleaseID: 594681